Amgen
Amgen Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of innovation since its founding in 1980. With a strong presence in major operational regions including Europe and Asia, Amgen focuses on developing therapies in areas such as oncology, nephrology, and inflammation. Renowned for its pioneering biologic medicines, Amgen's core products include Enbrel, Neulasta, and Prolia, which are distinguished by their ability to target specific disease pathways effectively. The company has achieved significant milestones, including the introduction of the first recombinant human erythropoietin, Epogen, which transformed the treatment of anaemia. As a prominent player in the biotechnology industry, Amgen continues to excel, holding a strong market position and receiving numerous accolades for its commitment to scientific excellence and patient care.
DitchCarbon Score
How does Amgen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amgen's score of 48 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amgen's reported carbon emissions
In 2024, Amgen reported total carbon emissions of approximately 121,000,000 kg CO2e, comprising about 107,000,000 kg CO2e from Scope 1 and about 14,000,000 kg CO2e from Scope 2. This marks a significant reduction from 2023, where total emissions were about 165,000,000 kg CO2e, with Scope 1 emissions at approximately 153,000,000 kg CO2e and Scope 2 at about 12,000,000 kg CO2e. Amgen has set ambitious climate commitments, aiming for a 55% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2027, using 2019 as the baseline year. The company also plans to achieve 100% renewable electricity sourcing across its operations by 2027, which is expected to result in a reduction of about 50% in carbon emissions from operations. As of 2023, Amgen achieved 54% of its targeted reductions for Scope 1 and 2 emissions. Additionally, Amgen is committed to ensuring that 73% of its suppliers, by spend, covering upstream purchased goods and services and capital goods, will have science-based targets by 2027. The company aims for carbon neutrality in its owned and operated facilities and operations (Scopes 1 and 2) by 2027. These targets align with the Science Based Targets initiative (SBTi) and reflect Amgen's commitment to addressing climate change within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 144,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 290,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amgen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
